Na Mee 22, 2025, Allist Pharmaceuticals kwupụtara na ọgwụ ọhụrụ ya bụ Airukai (Glecirasib Citrate Tablets), nke bụ ọgwụ mgbochi KRAS-G12C, ka akwadoro maka mmalite ahịa site n'aka National Medical Products Administration (NMPA). Nkwenye a na-enye ohere ka ejiri Airuikai gwọọ ndị okenye nwere ọrịa kansa akpa ume nke KRAS®®G12C nke a na-akpọ Advanced non-small cell lung cancer (NSCLC) bụ ndị natara ma ọ dịkarịa ala otu usoro ọgwụgwọ sistemụ. Nke a bụ ọgwụgwọ kansa akpa ume ọzọ a kwadoro maka Allist Pharmaceuticals, na-enye nhọrọ ọgwụgwọ ọhụrụ maka ndị ọrịa nwere ọrịa kansa akpa ume nke KRASG12C nke a na-akpọ ...
Nkwado a dabere na nsonaazụ sitere na nnyocha dị mkpa nke Phase II nke otu aka na-enyocha nchekwa, nnabata, na irè nke ọgwụgwọ Glecirasib n'ahụ ndị ọrịa nwere kansa akpa ume na-abụghị obere sel nke nwere KRASG12Cmutations bụ ndị dara ma ọ bụ na-anaghị anabata ọgwụgwọ ọkọlọtọ.
Nsonaazụ gosiri na Goleresai dị irè ma na-anabata nke ọma. Ruo Septemba 28, 2024, a gụnyere ngụkọta nke ndị ọrịa NSCLC 119 na nyocha ahụ. Ọnụego nzaghachi ebumnuche akwadoro (cORR), dịka Kọmitii Nyocha Onwe Onye (IRC) si nyochaa, bụ 49.6% (40.2%-59.0%), yana ọnụego njikwa ọrịa (DCR) nke 86.3% (78.7%-92.0%). Oge etiti nke nzaghachi (DOR) bụ ọnwa 14.5 (ọnwa 9.6 ruo na nke a na-apụghị ịkọ), ndụ etiti na-enweghị ọganihu (PFS) bụ ọnwa 8.2 (5.2–11.1), na ndụ etiti (OS) bụ ọnwa 17.5 (ọnwa 13.6 ruo na nke a na-apụghị ịkọ).
Ugbu a, enwere ọtụtụ nnwale ahụike nke teknụzụ ọhụrụ na-egbochi kansa na China na-achọ ndị ọrịa. Maka ndụmọdụ gbasara ọgwụ na teknụzụ ọhụrụ, ị nwere ike ịkpọtụrụ Ngalaba Mba Nile nke Ụlọ Ọgwụ Oncology nke Beijing South Region.
Nọmba ekwentị: 4008803716
Email：myimmnet@163.com
Oge ozi: Mee-27-2025